Eoneren
Shares of Alumis (NASDAQ:ALMS) traded ~14% increased within the premarket on Tuesday after the California-based biopharma introduced a collaboration and licensing settlement with Japanese drugmaker Kaken Pharmaceutical (OTCPK:KKPCF).
The deal focuses on the event, manufacturing, and commercialization of Alumis’ (
